Login
$MYGN
$5.57 -$0.09 (1.59%) Live

$MYGN SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 Form 4: Jampa Raj, Chief Technology Officer

Granted 58,560 Time-Based Stock Option

09 Nov 2026 Form 4: Sikri Vishal, EVP, Commercial

Granted 53,236 Time-Based Stock Option

09 Nov 2026 Form 4: Solaiman Shereen, Chief People Officer

Granted 83,049 Time-Based Stock Option

09 Nov 2026 Form 4: Fox Jennifer Lynne, Chief Legal & Corp Strategy

Granted 139,267 Time-Based Stock Option

09 Nov 2026 Form 4: Muzzey Dale, Chief Scientific Officer

Granted 92,632 Time-Based Stock Option

09 Nov 2026 Form 4: Verratti Mark, Chief Operating Officer

Granted 146,933 Time-Based Stock Option

09 Nov 2026 Form 4: Wheeler Benjamin Richard, Chief Financial Officer

Granted 121,379 Time-Based Stock Option

09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

2026 Employee, Director and Consultant Equity Incentive Plan

06 Nov 2026 10-Q
05 Nov 2026 8-K: Other Events

On November 2, 2026, Myriad Genetics, Inc. (the “Company”) detected unauthorized access within its information technology network environment. Upon discovery, the Company promptly initiated its incident response procedures to contain the...

04 Nov 2026 8-K: Results of Operations and Financial Condition

SALT LAKE CITY, November 4, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2026, and raised the mi...

02 Nov 2026 Form 4: Fox Jennifer Lynne, Chief Legal & Corp Strategy

Received 39,370 shares as a grant or award

27 Oct 2026 SCHEDULE 13G/A
20 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

______________________________________________________________________________

09 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Separation Agreement and Release of Claims (“Agreement”) is entered into by and between Myriad Genetics, Inc. (together with its subsidiaries, affiliates, successors and assigns, the “Company”) and Brian Donnelly (“Executive” and to...

22 Sep 2026 Form 4: Wheeler Benjamin Richard, Chief Financial Officer

Gave up 2,555 shares to cover exercise price or tax ($10.2K)

18 Sep 2026 Form 4: Donnelly Brian J, Chief Commercial Officer

Holds 573,363 shares of Common Stock

17 Sep 2026 Form 4: Sikri Vishal, EVP, Commercial

Received 257,731 shares as a grant or award

17 Sep 2026 Form 3: Sikri Vishal, EVP, Commercial

Holds 93,493 shares of Common Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support